secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2023-09-15T23:59:59+00:00
Accession:  0001140361-23-044141
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharmaceuticals raises ~$188.9M in public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Offered 7,812,500 shares at $16.00/share and pre-funded warrants for 3,126,955 shares at $15.99 each.
- Underwriters exercised full 30-day option to purchase an additional 1,640,918 shares.
- Net proceeds of ~$188.9M to fund gene therapy pipeline including RP-A501 Phase 2 trial.
- 90-day lock-up agreements for executive officers, directors, and certain shareholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036123044141/0001140361-23-044141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036123044141/ny20010507x5_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-044141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer